LNTH - Lantheus Holdings a buy at B Riley on growth spurred by approval of imaging agent

• B Riley has resumed coverage of Lantheus Holdings ( NASDAQ: LNTH ) with a buy citing the company's growth trajectory due to the the launch of Pylarify, a prostate-specific membrane antigen (PSMA) targeting positron emission tomography ( PET ) imaging agent.
• The firm has a $102 price target (23% upside based on Wednesday's close).
• Analyst Yuan Zhi noted that Definity, am ultrasound contrast agent, has ~80% market share and generated sales of $121M in 1H22. Pylarify had sales of $223M in the half.
• He added that Lantheus ( LNTH ) recently raised its re venue guidance for the year .
• "Although being agnostic to the particular imaging agent used, the main differentiation factor between approved agents is availability, and this is where we believe LNTH shows a distinct advantage over competing agents," Zhi said in regards to Pylarify.
• Seeking Alpha's Quant Rating views Lantheus ( LNTH ) as a strong buy.

For further details see: